1. Home
  2. PMTS vs TSHA Comparison

PMTS vs TSHA Comparison

Compare PMTS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CPI Card Group Inc.

PMTS

CPI Card Group Inc.

HOLD

Current Price

$13.86

Market Cap

183.1M

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.27

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMTS
TSHA
Founded
2007
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.1M
1.5B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
PMTS
TSHA
Price
$13.86
$5.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
9
Target Price
$32.00
$10.56
AVG Volume (30 Days)
51.7K
3.4M
Earning Date
11-04-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.20
N/A
Revenue
$515,576,000.00
$6,310,000.00
Revenue This Year
$13.70
N/A
Revenue Next Year
$8.51
N/A
P/E Ratio
$11.71
N/A
Revenue Growth
12.48
N/A
52 Week Low
$11.64
$1.05
52 Week High
$34.25
$6.02

Technical Indicators

Market Signals
Indicator
PMTS
TSHA
Relative Strength Index (RSI) 36.40 49.30
Support Level $14.60 $5.58
Resistance Level $14.83 $6.02
Average True Range (ATR) 0.66 0.31
MACD -0.29 -0.11
Stochastic Oscillator 2.23 36.07

Price Performance

Historical Comparison
PMTS
TSHA

About PMTS CPI Card Group Inc.

CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: